Second, the novel ability to characterize tumor-specific somatic mutations in vivo, at diagnosis, creates opportunity for larger, prospective studies investigating the prognostic value of specific somatic RB1 alterations or other pathogenic mutations, such as BCOR or CREBBP [24]. This evidence concerns the gene RB1 and neoplasm.